Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on ACADIA Pharmaceuticals (ACAD – Research Report), Rocket Pharmaceuticals (RCKT – Research Report) and Atreca (BCEL – Research Report).
ACADIA Pharmaceuticals (ACAD)
In a report released today, Ami Fadia from Needham maintained a Hold rating on ACADIA Pharmaceuticals. The company’s shares closed last Monday at $16.62.
According to TipRanks.com, Fadia is a 3-star analyst with an average return of
ACADIA Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $20.36, which is a 27.0% upside from current levels. In a report issued on August 1, J.P. Morgan also initiated coverage with a Hold rating on the stock with a $19.00 price target.
Rocket Pharmaceuticals (RCKT)
Chardan Capital analyst Geulah Livshits reiterated a Buy rating on Rocket Pharmaceuticals today and set a price target of $62.00. The company’s shares closed last Monday at $15.84.
According to TipRanks.com, Livshits is a 5-star analyst with an average return of
Rocket Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $51.75, which is a 223.2% upside from current levels. In a report issued on July 25, Stifel Nicolaus also maintained a Buy rating on the stock with a $56.00 price target.
In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Atreca, with a price target of $25.00. The company’s shares closed last Monday at $2.28, close to its 52-week low of $1.51.
According to TipRanks.com, Pantginis ‘ ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Atreca with a $17.00 average price target, implying a 553.8% upside from current levels. In a report released yesterday, Brookline Capital Markets also reiterated a Buy rating on the stock with a $17.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ACAD:
- Descrypto Holdings’ Subsidiary OpenLocker to Launch the Gatorverse to Empower University of Florida Student-Athletes to Engage with Fans through Innovative Collectibles
- Berenberg Bank Reaffirms Their Buy Rating on Denali Therapeutics (DNLI)
- H.C. Wainwright Remains a Buy on Ocular Therapeutix (OCUL)
- Repare Therapeutics (RPTX) Receives a Buy from H.C. Wainwright
- Artelo Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update